Mapi - Pharma (Mapi - Pharma) Cash Ratio : 5.56 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Mapi - Pharma's Cash Ratio for the quarter that ended in Jun. 2015 was 5.56.

Mapi - Pharma has a Cash Ratio of 5.56. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Mapi - Pharma's Cash Ratio or its related term are showing as below:

MAPI's Cash Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Cash Ratio only.

Mapi - Pharma Cash Ratio Historical Data

The historical data trend for Mapi - Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Cash Ratio Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Cash Ratio

3.07

1.49

0.55

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Cash Ratio	3.07	1.49	-	0.55	5.56

Competitive Comparison of Mapi - Pharma's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Cash Ratio falls into.

Mapi - Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Mapi - Pharma's Cash Ratio for the fiscal year that ended in Dec. 2014 is calculated as:

Cash Ratio (A: Dec. 2014 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	2.326	/	4.263
	=	0.55

Mapi - Pharma's Cash Ratio for the quarter that ended in Jun. 2015 is calculated as:

Cash Ratio (Q: Jun. 2015 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	12.304	/	2.214
	=	5.56

Mapi - Pharma (NAS:MAPI) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

Mapi - Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Cash Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.